An increasing number of articles on the treatment effect of stem cell therapy have been published in the recent decade. Although the techniques in orthopedic surgery, such as total knee arthro plasty (TKA) and anterior cruciate ligament (ACL) reconstruc tion, have shown great improvement, the restoration of normal biomechanics 1) and proprioception 2) is still the main issue. Hence the growing interest of researchers in regenerative medicine. Among the numerous methods that have been used for enhanc ing healing and regeneration, mesenchymal stem cell (MSC) therapy is one of the most commonly used strategies. MSCs have high proliferative potential and the ability to differentiate into chondrocytes, osteoblasts, and adipocytes One of the most conflicting subjects, which was also discussed in 2 of the 3 articles in the current issue, is the effect of age on the availability, proliferative capacity, and potential for differ entiation of MSCs 4, 6) . In the literature review by Huri et al., the independence of the decrease of agerelated stemness was the main advantage of IPFPASCs over BMMSCs. Based on the theory that the quantity and quality of MSCs declines with aging, Block et al. 7) even proposed a method that "rejuvenated" elderly BMMSCs. However, in the original article by Shin et al., they concluded that no substantial differences between ACLMSCs from young and those from old donors were observed in their proliferative capacity and multilineage differentiation potential. Furthermore, as stated by another review 3) , although aging ap pears to alter the differentiation potential of BMMSCs measured in vitro, whether this occurs in vivo is still debatable.
. In addition to their multilineage potential, MSCs have further therapeutic functions in response to injury, including immune modulation 4) and tro phic activities 5) . One of the most conflicting subjects, which was also discussed in 2 of the 3 articles in the current issue, is the effect of age on the availability, proliferative capacity, and potential for differ entiation of MSCs 4, 6) . In the literature review by Huri et al., the independence of the decrease of agerelated stemness was the main advantage of IPFPASCs over BMMSCs. Based on the theory that the quantity and quality of MSCs declines with aging, Block et al. 7) even proposed a method that "rejuvenated" elderly
BMMSCs. However, in the original article by Shin et al., they concluded that no substantial differences between ACLMSCs from young and those from old donors were observed in their proliferative capacity and multilineage differentiation potential. Furthermore, as stated by another review 3) , although aging ap pears to alter the differentiation potential of BMMSCs measured in vitro, whether this occurs in vivo is still debatable.
Currently, the clinical application of MSCs in orthopedic field is mainly degenerative OA. Compared with the number of preclini cal studies, the number of clinical trials is limited 8) . In the meta analysis of Shin et al., patients treated with BMMSCs showed significant functional improvement and pain relief when com pared with baseline, although MRI findings did not show signifi cant differences. After all, since there is a paucity of randomized controlled trials, there are still many questions to be answered in terms of the mechanism, best cell source, most appropriate processing method, most effective dose, delivery procedure, and longterm safety 9) . In addition, although few articles on the ap plication of MSCs in sports medicine field exist, the future of this field will be promising.
